Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + eribulin + carboplatin for previously treated advanced triple-negative breast cancer
ChiCTR2300076899Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, eribulin and carboplatin in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Oct 2023; status: recruiting.
02
Drugs
toripalimaberibulincarboplatin
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ChiCTR2300076899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076899.